Geneva, March 20 -- International Clinical Trials Registry received information related to the study (PACTR202602521522057) titled 'Multiparameter Flow Cytometry (MPFC) Minimal Residual Disease Status as a Prognostic Factor in Newly Diagnosed Egyptian Multiple Myeloma Patients: A 36-Month Follow-Up Study' on Feb. 26.
Study Type: Interventional
Study Design:
Single Group,Non-randomised,Allocation Sequence/Code was not concealed
Primary Sponsor: National Cancer Institute Cairo University
Condition:
Cancer
Recruitment Status: Not Recruiting
Phase: Not Applicable
Date of First Enrollment: 21/12/2020
Target Sample Size: 102
Countries of Recruitment:
Egypt
To know more, visit https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=...